<DOC>
	<DOCNO>NCT01824251</DOCNO>
	<brief_summary>Patients diagnose Chronic Inflammatory Demyelinating Polyneuropathy confirm base European Federation Neurological Societies/ Peripheral . Nerve Society Guideline . Patients meet inclusion criterion conflict exclusion criterion receive NPB-01 ( intravenous immunoglobulin ) 400mg/kg/day five consecutive day . Subsequently , patient receive NPB-01 1g/kg every 3weeks evaluate Inflammatory Neuropathy Cause Treatment（INCAT） score INCAT sensory sumscore（ISS） et al . As safety endpoint , safety NPB-01 investigate occurrence adverse event one year start study treatment .</brief_summary>
	<brief_title>Phase III Clinical Trial NPB-01maintenance Therapy Patients With Chronic Inflammatory Demyelinating Polyneuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients progressive relapse motor sensory dysfunction one limb result neuropathy within 2 month prior date informed consent obtain . 2 . Patients INCAT score 29 . ( If INCAT score 1 upper limb , INCAT score 2 must exclusively leg disability qualify . ) 3 . Patients need highdose intravenous immunoglobulin therapy . 4 . Patients continue treatment CIDP without addition increase 30 day inform consent . 5 . Patients great equal twenty year old informed consent . 1 . Patients evidence myelopathy demyelination central nerve 2 . Patients evidence stroke , central nerve system trauma , persistent neurological deficit due peripheral neuropathy causes（diabetic neuropathy , IgM paraproteinaemia , uraemic neuropathy , toxic neuropathy , hereditary neuropathy） 3 . Patients evidence neuropathy alcoholic neuropathy vitamin deficiency neuropathy due myeloma , lymphoma , sarcoidosis , systemic lupus erythematosus , malignancy , vasculitis , Crow‐Fukase syndrome , Sjögren syndrome . 4 . Patients multifocal motor neuropathy . 5 . Patients treat plasmapheresis 3 month inform consent . 6 . Patients treat rituximab 6 month inform consent . 7 . Patients treat highdose intravenous immunoglobulin（greater equal 1g/kg） 8 week inform consent . 8 . Patients treat intravenous immunoglobulin 3 week inform consent . 9 . Patients history shock hypersensitivity NPB01 . 10 . Patients IgA deficiency . 11 . Patients malignancy inform consent . 12 . Patients impaired liver function . 13 . Patients impaired renal function . 14 . Patients cerebro cardiovascular disorder . 15 . Patients high risk thromboembolism . 16 . Patients hemolytic/hemorrhagic anemia . 17 . Patients decrease cardiac function . 18 . Patients decreased platelet .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>IVIG Chronic Inflammatory Demyelinating Polyneuropathy</keyword>
	<keyword>Patients Chronic Inflammatory Demyelinating Polyneuropathy</keyword>
</DOC>